Condition: Gastric Cancer · Esophageal Adenocarcinoma · Hepatocellular Carcinoma · Sponsor: Anwaar Saeed
The investigators propose to evaluate the safety of drug combinations in patients with advanced gastroesophageal cancer and other gastrointestinal (GI) malignancies. Finding effective novel therapies for patients with advanced gastric cancer and other GI malignancies is an area of great unmet need. The investigators believe that modulating the tumor microenvironment with biologic agents like cabozantinib will have synergistic effect when combined with checkpoint-based immunotherapeutics like durvalumab in this patient population. This is a phase I/II, open label, multi-cohort trial looking at safety, tolerability and efficacy endpoints.
This description comes directly from the study's public registry record.
Debra Diecks, RN · 4126238364 · diecksda@upmc.edu
Clare Grzejka, RN · 4126234891 · grzejkac@upmc.edu
Always discuss trial participation with your own doctor first.
| University of Kansas Cancer Center | Westwood, Kansas, United States | Terminated |
| UPMC Hillman Cancer Center | Pittsburgh, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03539822